ArticleNordisk alkohol- & narkotikatidskrift : NAT2017
The slippery slope of flubromazolam: Experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum.
Article in Nordisk alkohol- & narkotikatidskrift : NAT, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Harm reduction approaches for the use of benzodiazepines: a scoping review.Harm reduction journal · 2025Article
- Experiences of long-term benzodiazepine use and addiction amid changes in guidelines for the prescription of narcotic drugs: a qualitative study.BMC public health · 2025Article
- Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects.Neurology international · 2022Review
- Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services.Drug testing and analysis · 2022Article
- A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues.Forensic toxicology · 2022Article
- Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Blood Concentrations of Designer Benzodiazepines: Relation to Impairment and Findings in Forensic Cases.Journal of analytical toxicology · 2020Article
- Designer drugs: mechanism of action and adverse effects.Archives of toxicology · 2020Review
- New psychoactive substances: a review and updates.Therapeutic advances in psychopharmacology · 2020Review
- Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.Harm reduction journal · 2019Article
- Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil.The mental health clinician · 2019Article
- Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches.Harm reduction journal · 2017Article
- Exploring new substance use settings.Nordisk alkohol- & narkotikatidskrift : NAT · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe purpose of this qualitative study was to investigate the effects experienced by users of a novel psychoactive substance, the benzodiazepine flubromazolam, by analysing users' own accounts on the Swedish forum Flashback.org.
methodA thematic analysis of anonymous self-reports published on the forum was performed and generated five general themes describing effects and experiences by flubromazolam users.
resultsThe themes which emerged were: Onset and duration, Desired effects, Adverse effects and addiction, Loss of control, General estimations and evaluations. The main reported characteristics of flubromazolam were heavy hypnotic and sedative effects, long-lasting amnesiac effects and the rapid development of tolerance. Flubromazolam was also anxiolytic and acted as a muscle relaxant for many users. Some users experienced euphoria or intense wellbeing. Other prominent characteristics were loss of control (leading to poor choices and actions, with unpleasant consequences) and long-lasting, often severe withdrawals. There were also serious incidents where users had been admitted to hospital, acute psychiatric treatment or taken into custody by the police.
conclusionFlubromazolam appears to be a highly addictive and precarious benzodiazepine with many, possibly severe, side effects. The substance is generally described as very potent and with long-lasting effects. Memory loss and loss of control are common adverse effects, and withdrawals appear to be severe for many users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.